If left untreated leads to irreversible blindness Glaucoma
 100 million people worldwide have glaucoma 3 million people in the US have glaucoma 40% will go blind in one eye 15% will go blind in both eyes
But it does not have to be this way Vision through Innovation

eyeFlow, Inc. is developing a highly effective micro-invasive device for the treatment of the world’s largest cause of irreversible blindness that is:

Potentially Drop-Free

Surgery using eyeFlow’s device may eliminate the need for high cost drop medications that come with severe side effects

Simple and Straightforward

eyeFlow takes Micro Invasive Glaucoma Surgery to the next level with the most accessible, intuitive procedure to date

Atop A High Growth Market

eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market

Atop A High Growth Market

eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market

In early pre-clinical trials, eyeFlow’s Micro Invasive Glaucoma Surgery (MIGS) device has produced very promising results and astonished a World-Renowned Ophthalmologist:

“My early implant experience with eyeflow has been outstanding. I believe its unique design and delivery system is going to appeal to a wide range of physicians and patients as it offers the most consistent mode of implantation.”

Arsham Sheybani, MD
Key Opinion Leader – Micro Invasive Glaucoma Surgery

Join us in Preserving Vision

Explore how investing in eyeFlow can help prevent blindness for millions through groundbreaking technology, while offering unique investment opportunities.
Contact Form Demo

your message will be received by info@eyeflow-inc.com

© 2025 eyeFlow All rights reserved.